Statistical modeling using early markers of innate immunity to explain variation in humoral responses to influenza vaccine in older adults
Greater understanding of the factors associated with a protective response to influenza vaccine in older adults could have tremendous public health benefits. We studied 158 participants age 50-74 years vaccinated with 2010-2011 inactivated influenza vaccine and performed innate immunity and humoral immunity assays directed against influenza A/California/2009 (H1N1) as measured through hemagglutination inhibition (HAI), microneutralization, and B cell ELISPOT at days 0, 3, and 28 postvaccination. We report the results of statistical modeling using Day 3 cytokines, chemokines, and innate cell populations to model Day 0 to Day 28 HAI seroconversion, viral neutralization seroconversion, and B cell ELISPOT results..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Vaccine - 33(2015), 31, Seite 3682 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goergen, Krista M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult |
|---|
| doi: |
10.1016/j.vaccine.2015.06.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1969888393 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1969888393 | ||
| 003 | DE-627 | ||
| 005 | 20230714175235.0 | ||
| 007 | tu | ||
| 008 | 160211s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2015.06.031 |2 doi | |
| 028 | 5 | 2 | |a PQ20160211 |
| 035 | |a (DE-627)OLC1969888393 | ||
| 035 | |a (DE-599)GBVOLC1969888393 | ||
| 035 | |a (PRQ)c2093-51fad6098c87eb3521e82763c7c8f67ec7e638dc2ef1e2bfa6e4ac306ee468310 | ||
| 035 | |a (KEY)0128923320150000033003103682statisticalmodelingusingearlymarkersofinnateimmuni | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Goergen, Krista M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statistical modeling using early markers of innate immunity to explain variation in humoral responses to influenza vaccine in older adults |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Greater understanding of the factors associated with a protective response to influenza vaccine in older adults could have tremendous public health benefits. We studied 158 participants age 50-74 years vaccinated with 2010-2011 inactivated influenza vaccine and performed innate immunity and humoral immunity assays directed against influenza A/California/2009 (H1N1) as measured through hemagglutination inhibition (HAI), microneutralization, and B cell ELISPOT at days 0, 3, and 28 postvaccination. We report the results of statistical modeling using Day 3 cytokines, chemokines, and innate cell populations to model Day 0 to Day 28 HAI seroconversion, viral neutralization seroconversion, and B cell ELISPOT results. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Ltd. All rights reserved. | ||
| 650 | 4 | |a Age | |
| 650 | 4 | |a Chemokines | |
| 650 | 4 | |a Influenza vaccines | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Models, Statistical | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a Age factors | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Older people | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Immunity, Humoral | |
| 650 | 4 | |a Infections | |
| 700 | 1 | |a Grill, Diane E |4 oth | |
| 700 | 1 | |a Oberg, Ann L |4 oth | |
| 700 | 1 | |a Tosh, Pritish K |4 oth | |
| 700 | 1 | |a Kennedy, Richard B |4 oth | |
| 700 | 1 | |a Poland, Gregory A |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d Amsterdam : Elsevier, 1983 |g 33(2015), 31, Seite 3682 |w (DE-627)130402427 |w (DE-600)605674-X |w (DE-576)015904938 |x 0264-410X |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:31 |g pages:3682 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.vaccine.2015.06.031 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26087295 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1693887733 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 31 |h 3682 | ||